Harvey Berger

From Wikipedia, the free encyclopedia
For the scientist and inventor, see Harvey L. Berger.
Harvey Berger
Born (1950-06-06) June 6, 1950 (age 73)
Alma materColgate University (1972, B.A.)
Yale School of Medicine (1977, M.D.)
Occupation(s)Founder and Former Chairman & CEO of ARIAD Pharmaceuticals
Board member ofDana–Farber Cancer Institute
SpouseChrysanthi Berger (m. 2002)
Children2, including Nicole Berger

Harvey J. Berger is an American physician-scientist, entrepreneur and biotechnology executive. He was the founder and chairman and chief executive officer of ARIAD Pharmaceuticals, Inc. for 25 years, starting in 1991 and became advisor to the board in 2016. He was also executive chairman at Medinol, Inc from 2017 to 2018. In February 2018, Berger was appointed to the Dana–Farber Cancer Institute Board of Trustees.

Early life and education[edit]

Berger received his B.A. in Biology from Colgate University in 1972 and received his M.D. from Yale School of Medicine in 1977.[1][2] He completed further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital.[2]

Career[edit]

From 1986 until 1991, Berger held executive management positions at Centocor, Inc. including executive vice president and president of the Research and Development Division.[3] He led the development of Remicade® (infliximab), formerly known as Centara, a drug for the treatment of autoimmune diseases such as Crohn's disease, ulcerative colitis and rheumatoid arthritis, ReoPro® (abciximab), formerly known as CentoRx, a drug for the prevention of ischemic complications in patients with CAD undergoing percutaneous interventions,[4][5] and the cancer diagnostic test, CA125, to evaluate patients with ovarian cancer.[6][7]

In 1991, Berger founded ARIAD Pharmaceuticals in Cambridge, Massachusetts.[8][9] He served as chairman and CEO from 1991 to 2015.[9][2] In 1992, ARIAD raised $46 million, the largest single round of financing for a startup in the biotechnology industry at the time.[10] ARIAD's plan was to develop drugs that would interfere with communication signals within cells, rather than on the cell surface or in between cells.[10] In 1994, ARIAD filed for an initial public offering and was listed on the NASDAQ market.[11][12]

In 2000, Berger focused ARIAD on oncology, based on recent discoveries in the human genome.[13] Under Berger's leadership, ARIAD grew to over 365 U.S. employees and established a European headquarters in Lausanne, Switzerland.[14][15]

While Berger was CEO, ARIAD developed five new medicines including the blood-cancer drug Iclusig, Brigatinib, a lung cancer treatment and AP32788 (now known as TAK788), a new medicine for lung cancer with novel mutated genetic targets.[9][16]

Brigatinib is approved for use in the U.S.[17] and Europe,[18][19] and TAK788 is continuing a global phase 3 trial.[20]

At the end of 2015, Berger retired from ARIAD and became an advisor to the board of directors.[9][21] In early 2017, ARIAD was acquired by Takeda Pharmaceuticals, Ltd. for $5.2 billion, becoming part of Takeda Oncology.[22]

In February 2017, Medinol, Inc. announced that Berger would be serving as its executive chairman.[23] On the global management team, his focuses at Medinol would include business management, global strategy, new business and technology initiatives, as well as improving operational efficiency as the company expands worldwide.[24][3] Berger's role at Medinol was said to include working with their core business of interventional cardiovascular devices, along with its new businesses developing percutaneous aortic valves, sub-millimeter implantable sensors, and related products.[24] He retired from Medinol at the end of 2018.[25] In 2019, Berger retired as chairman and chief executive officer emeritus of ARIAD.[25]

Berger has served on the Board of Trustees at Concord Academy.[26]

Berger has held senior academic and administrative roles at Emory University, Yale University and the University of Pennsylvania.[3][24] He was also a member of the Dean's Council of Yale University School of Medicine.[2] During his time at Emory, Berger led a program for developing cardiovascular single-photon emission computed tomographic (SPECT) imaging, supported by General Electric Medical Systems.[27] He and other colleagues at Emory collaborated on the development of new quantitative techniques for cardiac SPECT imaging.[28]

Berger has contributed to a wide range of medical journals including the New England Journal of Medicine and American Journal of Cardiology,[29][30] and has been interviewed by Fox Business[31][32][33][34] and CNBC.[35] He was also an established investigator of the American Heart Association.[3]

Awards[edit]

In 2013, Berger was awarded the Ernst & Young Entrepreneur of the Year Award for the New England Region. The award recognizes success in innovation, financial performance, personal commitment to their business communities and other areas.[36] Also in 2013, Berger was awarded a Gold Stevie Award.[37][38]

Personal life and philanthropy[edit]

Berger resides in Palm Beach, Florida, with his wife Chrysanthi and their two daughters, Isabella Grace Berger and Nicole Elizabeth Berger, an actress.[39][40] Harvey and Chrysanthi Berger have supported the Palm Beach Day Academy, the American Cancer Society, and the Dana–Farber Cancer Institute.[41][42][43] In February 2018, Berger was appointed to the Dana–Farber Cancer Institute Board of Trustees, the governing board of the organization.[44]

References[edit]

  1. ^ "A showcase of alumni talent (The Colgate Scene, September 2002)". www4.colgate.edu. Retrieved 2017-09-25.
  2. ^ a b c d "MIT Sloan BioInnovations 2011". web.mit.edu. Retrieved 2017-09-20.
  3. ^ a b c d Bader, Emily (2017-02-16). "Medinol appoints executive chairman of Medinol US | NJBIZ". NJBIZ. Retrieved 2017-09-23.
  4. ^ Letter, The Pharma. "US Approval For Centocor's ReoPro – Pharmaceutical industry news". www.thepharmaletter.com. Retrieved 2017-09-25.
  5. ^ "Biotechnology Report, Medicines in Development, 2006 | Interleukin 2 | Monoclonal Antibody". Scribd. Retrieved 2017-09-25.
  6. ^ "Centocor CA 125 II, New Version of CA 125 Assay, Is Now Available | Cancer Network". www.cancernetwork.com. Oncology NEWS International Vol 4 No 5. 4 (5). May 1995. Retrieved 2018-03-20.
  7. ^ Matsukura, A.; Nakazawa, Y.; Hama, S. (November 1989). "[A shortened method for the assay with Centocor radioimmunoassay kit]". Radioisotopes. 38 (11): 469–472. doi:10.3769/radioisotopes.38.11_469. ISSN 0033-8303. PMID 2595020.
  8. ^ "Ariad moving to new Kendall Square headquarters – The Boston Globe". BostonGlobe.com. Retrieved 2017-09-24.
  9. ^ a b c d "Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'". www.bizjournals.com. Retrieved 2017-09-24.
  10. ^ a b Pollack, Rew (1992-03-27). "COMPANY NEWS; Ariad Raises $46 Million In Placement". The New York Times. ISSN 0362-4331. Retrieved 2017-09-25.
  11. ^ "Equity Issues This Week". The New York Times. 1994-05-16. ISSN 0362-4331. Retrieved 2017-09-25.
  12. ^ "Ariad Pharmaceuticals, Inc. (ARIA) Stock Higher on Takeda Buyout News". NASDAQ.com. 2017-01-09. Retrieved 2017-09-25.
  13. ^ "Interview: Harvey Berger and Timothy Clackson, Ariad". www.pmlive.com. 2013-10-14. Retrieved 2017-09-20.
  14. ^ "Ariad's Harvey Berger says he's 'absolutely' secure in his role as CEO". www.bizjournals.com. Retrieved 2017-09-25.
  15. ^ "Ariad sells European operations for $140M upfront plus royalties". www.bizjournals.com. Retrieved 2017-09-25.
  16. ^ "Positive Preclinical Results for Lung Cancer Drug Announced at Annual Meeting of Cancer Research – Lung Disease News". Lung Disease News. 2016-04-22. Retrieved 2017-09-24.
  17. ^ Research, Center for Drug Evaluation and (2020-05-26). "FDA approves brigatinib for ALK-positive metastatic NSCLC". FDA.
  18. ^ "BRIEF-Takeda Says European Commission Approved Alunbrig As A First-Line Treatment For ALK+ NSCLC". Reuters. 2020-04-06. Retrieved 2020-06-26.
  19. ^ McKee, Selina (2020-04-08). "Expanded EU approval for Takeda's Alunbrig". PharmaTimes. Retrieved 2020-06-26.
  20. ^ "Takeda's Approval and Other News: The Good, Bad And Ugly of Biopharma". 25 May 2020.
  21. ^ "ARIAD Founder, Harvey J. Berger, M.D., to Retire as Chairman and Chief Executive Officer". ARIAD Pharmaceuticals, Inc. Retrieved 2017-09-24.
  22. ^ "Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'". www.bizjournals.com. Retrieved 2017-09-23.
  23. ^ "Berger named to post at Medinol – The Boston Globe". BostonGlobe.com. Retrieved 2017-09-25.
  24. ^ a b c "Medinol hires Harvey Berger as executive chairman of its US operations". Cardiovascular Business. Retrieved 2017-09-23.
  25. ^ a b "Harvey Berger | About". Harvey Berger. Retrieved 2020-06-26.
  26. ^ "CA Magazine Fall 2018". Issuu. 5 November 2018. Retrieved 2020-06-26.
  27. ^ DePasquale, E. E.; Nody, A. C.; DePuey, E. G.; Garcia, E. V.; Pilcher, G.; Bredlau, C.; Roubin, G.; Gober, A.; Gruentzig, A. (1988-02-01). "Quantitative rotational thallium-201 tomography for identifying and localizing coronary artery disease". Circulation. 77 (2): 316–327. doi:10.1161/01.CIR.77.2.316. ISSN 0009-7322. PMID 3257422.
  28. ^ Berger, Harvey J.; Eisner, Robert; DePuey, E. Gordon; Patterson, Randolph (1984-11-01). "New Vistas in Cardiovascular Nuclear Medicine". Journal of Nuclear Medicine. 25 (11): 1254–1258. ISSN 0161-5505. PMID 6333498.
  29. ^ Ziegler, Elizabeth J.; Fisher, Charles J.; Sprung, Charles L.; Straube, Richard C.; Sadoff, Jerald C.; Foulke, Garrett E.; Wortel, Cornelis H.; Fink, Mitchell P.; Dellinger, R. Phillip (1991). "Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin". New England Journal of Medicine. 324 (7): 429–436. doi:10.1056/nejm199102143240701. PMID 1988827.
  30. ^ Johnstone, David E.; Sands, Milton J.; Berger, Harvey J.; Reduto, Lawrence A.; Lachman, Anthony S.; Wackers, Frans J. Th; Cohen, Lawrence S.; Gottschalk, Alexander; Zaret, Barry L. (1980-06-01). "Comparison of exercise radionuclide angiocardiography and thallium-201 myocardial perfusion imaging in coronary artery disease". American Journal of Cardiology. 45 (6): 1113–1119. doi:10.1016/0002-9149(80)90467-1. ISSN 0002-9149. PMID 7377108.
  31. ^ "Ariad CEO on Developing New Drugs". Fox Business. 2011-07-15. Retrieved 2017-11-10.
  32. ^ "Ariad CEO on the Three Drugs in the Pipeline for Cancer Treatment". Fox Business. 2011-11-10. Retrieved 2017-11-10.
  33. ^ "Ariad Pharmaceuticals Working on Cancer 'Miracle Pill'". Fox Business. 2012-08-03. Retrieved 2017-11-10.
  34. ^ "Ariad Pharmaceuticals CEO on a New Leukemia Drug". Fox Business. 2012-06-08. Retrieved 2017-11-10.
  35. ^ Chang, Kirsten (2012-06-04). "Cramer Interviews Ariad Pharma CEO". CNBC. Retrieved 2017-11-10.
  36. ^ AOL Staff. "ARIAD Chief Executive Officer, Harvey J. Berger, M.D., Recognized as 2013 Ernst & Young Entrepreneur". AOL.com. Retrieved 2017-09-21.
  37. ^ "ARIAD Honored With Gold Stevie Awards As Pharmaceutical Company Of The Year At 2013 American Business Awards". The Street. 18 June 2013. Archived from the original on 26 September 2017.
  38. ^ "Harvey J. Berger, M.D. '77 Appointed Executive Chairman, Medinol Inc". Yale School of Medicine. Retrieved 2020-06-26.
  39. ^ "Palm Beach 13-year-old gets Broadway bash – and a visit from Flo Rida". palmbeachdailynews. Retrieved 2017-09-23.
  40. ^ "Alumni > Autumn 2008 | Yale Medicine". ymm.yale.edu. Retrieved 2017-11-10.
  41. ^ "'Jukebox Hero' Gramm brings '80s to life for American Cancer Society". palmbeachdailynews. Retrieved 2017-11-10.
  42. ^ "MAD, PMP, HSS, and PBDA". New York Social Diary. 2017-03-20. Retrieved 2017-11-10.
  43. ^ Donnelly, Shannon. "Palm Beach society: Katie Couric shares slices of life at Dana–Farber Cancer Institute donors dinner". Sarasota Herald-Tribune. Retrieved 2020-06-26.
  44. ^ "Dana–Farber Cancer Institute appoints six new members to Board of Trustees – Dana–Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved 2018-03-20.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Harvey_Berger&oldid=1223466838"